Avid Bioservices Inc (CDMO)

[investingdog]

Phase III agreement

"Peregrine Pharmaceuticals (Nasdaq: PPHM) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer (NSCLC). The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. Final data from the study will be presented at the upcoming ASCO Annual Meeting on Saturday, June 1, 2013."

http://www.streetinsider.com/Corporate+News/Peregrine+Pharma+%28PPHM%29%2C+FDA+Reach+Agreement+Over+Bavituximab+Phase+III+Design/8353432.html